Literature DB >> 12167101

Increased expression of integrin beta-4 in papillary thyroid carcinoma with gross lymph node metastasis.

Shin-Ichiro Kitajiri1, Naoki Hosaka, Harukazu Hiraumi, Tomoko Hirose, Susumu Ikehara.   

Abstract

Although the prognosis is generally good for patients with papillary thyroid carcinoma, gross nodal metastasis of carcinoma has a poor prognosis. It is necessary to clarify how carcinoma progresses to gross nodal metastasis in order to establish a cure. The adhesion molecule integrin beta-4 is considered to be related to cell migration and metastasis in many carcinomas. In the present study, we examined integrin beta-4 expression in 65 cases of human papillary thyroid carcinoma using immunohistochemical methods. Expression of integrin beta-4 was found in all papillary carcinomas, but in few normal thyrocytes. Interestingly, integrin beta-4 expression in the carcinomas with gross (> or =3 cm) lymph node metastasis was significantly higher than that in carcinomas with small (<3 cm) or no lymph node metastasis. These results suggest that integrin beta-4 expression in thyroid carcinoma may play a role in the development of gross lymph node metastasis of papillary carcinomas.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12167101     DOI: 10.1046/j.1440-1827.2002.01379.x

Source DB:  PubMed          Journal:  Pathol Int        ISSN: 1320-5463            Impact factor:   2.534


  14 in total

Review 1.  Clinical significance of the integrin α6β4 in human malignancies.

Authors:  Rachel L Stewart; Kathleen L O'Connor
Journal:  Lab Invest       Date:  2015-06-29       Impact factor: 5.662

2.  Critical role for integrin-β4 in the attenuation of murine acute lung injury by simvastatin.

Authors:  Weiguo Chen; Saad Sammani; Sumegha Mitra; Shwu Fan Ma; Joe G N Garcia; Jeffrey R Jacobson
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2012-06-08       Impact factor: 5.464

3.  Upregulation of integrin β4 promotes epithelial-mesenchymal transition and is a novel prognostic marker in pancreatic ductal adenocarcinoma.

Authors:  Y Masugi; K Yamazaki; K Emoto; K Effendi; H Tsujikawa; M Kitago; O Itano; Y Kitagawa; M Sakamoto
Journal:  Lab Invest       Date:  2015-01-19       Impact factor: 5.662

4.  Integrin beta4 attenuates SHP-2 and MAPK signaling and reduces human lung endothelial inflammatory responses.

Authors:  Weiguo Chen; Joe G N Garcia; Jeffrey R Jacobson
Journal:  J Cell Biochem       Date:  2010-06-01       Impact factor: 4.429

Review 5.  Extranuclear signaling of mutated thyroid hormone receptors in promoting metastatic spread in thyroid carcinogenesis.

Authors:  Changxue Lu; Sheue-Yann Cheng
Journal:  Steroids       Date:  2011-04-05       Impact factor: 2.668

6.  Upregulation and redistribution of integrin alpha6beta4 expression occurs at an early stage in pancreatic adenocarcinoma progression.

Authors:  Zobeida Cruz-Monserrate; Suimin Qiu; B Mark Evers; Kathleen L O'Connor
Journal:  Mod Pathol       Date:  2007-04-13       Impact factor: 7.842

7.  Cell surface glycoproteomic analysis of prostate cancer-derived PC-3 cells.

Authors:  Sarah C Hubbard; Michael Boyce; Cheryl T McVaugh; Donna M Peehl; Carolyn R Bertozzi
Journal:  Bioorg Med Chem Lett       Date:  2011-05-18       Impact factor: 2.823

8.  Study on the expression and clinical significances of lewis y antigen and integrin αv, β3 in epithelial ovarian tumors.

Authors:  Yifei Wang; Juanjuan Liu; Bei Lin; Changzhi Wang; Quanrong Li; Shuice Liu; Limei Yan; Shulan Zhang; Masao Iwamori
Journal:  Int J Mol Sci       Date:  2011-05-27       Impact factor: 5.923

9.  Integrin β4 promotes cell invasion and epithelial-mesenchymal transition through the modulation of Slug expression in hepatocellular carcinoma.

Authors:  Xiao-Long Li; Lin Liu; Dan-Dan Li; Ya-Ping He; Le-Hang Guo; Li-Ping Sun; Lin-Na Liu; Hui-Xiong Xu; Xiao-Ping Zhang
Journal:  Sci Rep       Date:  2017-01-13       Impact factor: 4.379

Review 10.  Laminin-binding integrins and their tetraspanin partners as potential antimetastatic targets.

Authors:  Christopher S Stipp
Journal:  Expert Rev Mol Med       Date:  2010-01-18       Impact factor: 5.600

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.